# Medicus Pharma Ltd.: financial statements, quarterly

MDCX · Nasdaq · CIK 1997296 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/mdcx.md) · [Financials](/companies/mdcx/financials.md) · [Filings](/companies/mdcx/filings.md) · [Insiders](/companies/mdcx/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/mdcx/financials.md?period=annual).

## Income statement

| Line item | Unit | period not labelled (2024-03-31) | period not labelled (2024-06-30) | period not labelled (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Research and development | $m | [0.3](/filings/0001062993-25-009125.md) | [1.3](/filings/0001062993-25-014058.md) | [0.6](/filings/0001062993-25-016838.md) | [1.4 d](/filings/0001062993-26-001606.md) | [2.0](/filings/0001062993-26-002629.md) | [1.4](/filings/0001062993-26-004230.md) | [1.7](/filings/0001062993-25-016838.md) | [2.6 d](/filings/0001062993-26-001606.md) | [2.7](/filings/0001062993-26-002629.md) | [4.9](/filings/0001062993-26-004230.md) |
| Operating income | $m | [(1.7)](/filings/0001062993-25-009125.md) | [(3.6)](/filings/0001062993-25-014058.md) | [(2.3)](/filings/0001062993-25-016838.md) | [(3.6) d](/filings/0001062993-26-001606.md) | [(5.1)](/filings/0001062993-26-002629.md) | [(6.0)](/filings/0001062993-26-004230.md) | [(0.0)](/filings/0001062993-25-016838.md) | [(7.8) d](/filings/0001062993-26-001606.md) | [(8.6)](/filings/0001062993-26-002629.md) | [(11.5)](/filings/0001062993-26-004230.md) |
| Interest expense | $m | not reported | not reported | not reported | not reported | [0.0](/filings/0001062993-26-002629.md) | [0.0](/filings/0001062993-26-004230.md) | not reported | not reported | [0.4](/filings/0001062993-26-002629.md) | [0.2](/filings/0001062993-26-004230.md) |
| Net income | $m | [(1.7)](/filings/0001062993-25-009125.md) | [(3.6)](/filings/0001062993-25-016838.md) | [(2.3)](/filings/0001062993-25-016838.md) | [(3.5) d](/filings/0001062993-26-001606.md) | [(5.1)](/filings/0001062993-26-002629.md) | [(6.2)](/filings/0001062993-26-004230.md) | [(20.9)](/filings/0001062993-25-016838.md) | [(15.1) d](/filings/0001062993-26-001606.md) | [(9.0)](/filings/0001062993-26-002629.md) | [(11.6)](/filings/0001062993-26-004230.md) |
| Diluted EPS | $ per share | [(0.21)](/filings/0001062993-25-009125.md) | [(0.44)](/filings/0001062993-25-014058.md) | [(0.24)](/filings/0001062993-25-016838.md) | not reported | [(0.42)](/filings/0001062993-26-002629.md) | [(0.43)](/filings/0001062993-26-004230.md) | [(1.12)](/filings/0001062993-25-016838.md) | not reported | [(0.31)](/filings/0001062993-26-002629.md) | [(0.21)](/filings/0001062993-26-004230.md) |
| Basic EPS | $ per share | [(0.21)](/filings/0001062993-25-009125.md) | [(0.44)](/filings/0001062993-25-014058.md) | [(0.24)](/filings/0001062993-25-016838.md) | not reported | [(0.42)](/filings/0001062993-26-002629.md) | [(0.43)](/filings/0001062993-26-004230.md) | [(1.12)](/filings/0001062993-25-016838.md) | not reported | [(0.31)](/filings/0001062993-26-002629.md) | [(0.21)](/filings/0001062993-26-004230.md) |

- Research and development: us-gaap:ResearchAndDevelopmentExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Interest expense: us-gaap:InterestExpense
- Net income: us-gaap:NetIncomeLoss, us-gaap:ProfitLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | period not labelled (2022-12-31) | period not labelled (2023-12-31) | period not labelled (2024-03-31) | period not labelled (2024-06-30) | period not labelled (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | not reported | [1.7](/filings/0001062993-25-006485.md) | not reported | not reported | not reported | [4.2](/filings/0001062993-26-001606.md) | [4.0](/filings/0001062993-25-009125.md) | [9.7](/filings/0001062993-25-014058.md) | [8.7](/filings/0001062993-25-016838.md) | [8.7](/filings/0001062993-26-004230.md) | [6.4](/filings/0001062993-26-002629.md) | [15.2](/filings/0001062993-26-004230.md) |
| Current assets | $m | not reported | [1.9](/filings/0001062993-25-006485.md) | not reported | not reported | not reported | [5.4](/filings/0001062993-26-001606.md) | [5.1](/filings/0001062993-25-009125.md) | [11.0](/filings/0001062993-25-014058.md) | [9.8](/filings/0001062993-25-016838.md) | [9.9](/filings/0001062993-26-004230.md) | [7.3](/filings/0001062993-26-002629.md) | [17.0](/filings/0001062993-26-004230.md) |
| Total assets | $m | not reported | [1.9](/filings/0001062993-25-006485.md) | not reported | not reported | not reported | [5.6](/filings/0001062993-26-001606.md) | [5.7](/filings/0001062993-25-009125.md) | [11.9](/filings/0001062993-25-014058.md) | [10.0](/filings/0001062993-25-016838.md) | [10.1](/filings/0001062993-26-004230.md) | [7.4](/filings/0001062993-26-002629.md) | [27.1](/filings/0001062993-26-004230.md) |
| Current liabilities | $m | not reported | [0.8](/filings/0001062993-25-006485.md) | not reported | not reported | not reported | [2.3](/filings/0001062993-26-001606.md) | [3.3](/filings/0001062993-25-009125.md) | [8.5](/filings/0001062993-25-014058.md) | [10.7](/filings/0001062993-25-016838.md) | [9.9](/filings/0001062993-26-004230.md) | [6.0](/filings/0001062993-26-002629.md) | [10.8](/filings/0001062993-26-004230.md) |
| Total liabilities | $m | not reported | [0.8](/filings/0001062993-25-006485.md) | not reported | not reported | not reported | [2.5](/filings/0001062993-26-001606.md) | [3.5](/filings/0001062993-25-009125.md) | [8.7](/filings/0001062993-25-014058.md) | [10.8](/filings/0001062993-25-016838.md) | [10.0](/filings/0001062993-26-004230.md) | [6.0](/filings/0001062993-26-002629.md) | [28.8](/filings/0001062993-26-004230.md) |
| Current portion of debt | $m | not reported | not reported | not reported | not reported | not reported | [0.0](/filings/0001062993-26-001606.md) | not reported | [4.7](/filings/0001062993-25-014058.md) | [6.8](/filings/0001062993-25-016838.md) | [5.2](/filings/0001062993-26-002629.md) | [2.3](/filings/0001062993-26-002629.md) | not reported |
| Shareholders' equity | $m | [(12.2)](/filings/0001062993-25-006485.md) | [1.1](/filings/0001062993-26-001606.md) | [(0.6)](/filings/0001062993-25-016838.md) | [7.1](/filings/0001062993-25-016838.md) | [4.8](/filings/0001062993-25-016838.md) | [3.1](/filings/0001062993-26-001606.md) | [2.1](/filings/0001062993-26-004230.md) | [3.2](/filings/0001062993-26-004230.md) | [(0.9)](/filings/0001062993-25-016838.md) | [(0.1)](/filings/0001062993-26-004230.md) | [1.3](/filings/0001062993-26-002629.md) | [(1.8)](/filings/0001062993-26-004230.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Current portion of debt: us-gaap:DebtCurrent
- Shareholders' equity: us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest, us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | period not labelled (2024-03-31) | period not labelled (2024-06-30) | period not labelled (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $k | [(1,177)](/filings/0001062993-25-009125.md) | [(2,777) d](/filings/0001062993-25-014058.md) | [(3,102) d](/filings/0001062993-25-016838.md) | [(3,192) d](/filings/0001062993-26-001606.md) | [(3,941)](/filings/0001062993-26-002629.md) | [(5,469) d](/filings/0001062993-26-004230.md) | [(6,758) d](/filings/0001062993-25-016838.md) | [(6,609) d](/filings/0001062993-26-001606.md) | [(8,970)](/filings/0001062993-26-002629.md) | [(6,983) d](/filings/0001062993-26-004230.md) |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities

## Shares

| Line item | Unit | period not labelled (2024-03-31) | period not labelled (2024-06-30) | period not labelled (2024-09-30) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [8.1](/filings/0001062993-25-009125.md) | [8.2](/filings/0001062993-25-014058.md) | [9.5](/filings/0001062993-25-016838.md) | [12.2](/filings/0001062993-26-002629.md) | [14.3](/filings/0001062993-26-004230.md) | [18.6](/filings/0001062993-25-016838.md) | [29.5](/filings/0001062993-26-002629.md) | [55.1](/filings/0001062993-26-004230.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 63,180,610 at 2026-08-10, from the cover of the [10-Q filed 2026-08-12](/filings/0001062993-26-004230.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:50 ET. No prices; not investment advice.